Reach Us +447897072958
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal

Research Article - (2019) Volume 9, Issue 3

Amish Uprety*
*Correspondence: Amish Uprety, Nargund College of pharmacy Bangalore, Karnataka, India, Tel: +917022670315, Email:
Nargund College of pharmacy Bangalore, Karnataka, India


Introduction: Hypertension is a chronic illness associated with high morbidity & mortality, with a rising number of patients with hypertension and chronic kidney disease, achieving blood pressure of less than 140/90 mm of Hg is challenging. Hence, there is a need for appropriate, safe, effective and economical study to find out the patterns of drug therapy.

Objectives: To evaluate utilization patterns of antihypertensive agents in chronic kidney disease patients.

Methodology: A prospective observational study was conducted for a period of 6 months in Jayanagar General Hospital, Bengaluru. We included 70 hypertensive CKD patients. Detailed patient information data were noted, and data entered in a preformed proforma in Microsoft Excel sheet for compilation and subjected to statistical analysis.

Results: Total 70 case records of patients having chronic kidney disease were analysed. Mean age was 52.08 ± 15.14. CKD was more prevalent in males 38 (54.2%) and 32 (46.8%) females with male to female ratio of 2.3:2. Most of the patients (52.80%) belonged tote age group of 41-60 years. Among the anti-hypertensive agents, most frequently used was calcium channel blockers (91.4%), followed by diuretics (54.2%), Beta blockers (31.4%), alpha blockers, ACE inhibitors and ARB.

Conclusion: Dual and triple therapy were prescribed which was according to ESH guidelines. This study highlights some therapeutic rationality in this health centre. However, targeted education of the prescription-givers and dissemination of treatment guideline could facilitate rational use of drugs and adherence to treatment guidelines.


Hypertension; Chronic kidney disease; Drug utilization; ESH Guidelines; Treatment.


According to WHO, Hypertension is defined as a systolic blood pressure (SBP) of 140 mmHg or more, or a diastolic blood pressure (DBP) of 90 mmHg or more. Hypertension is a common disease that is simply defined as persistently elevated arterial blood pressure (BP). Although elevated BP was perceived to be “essential” for adequate perfusion of essential organs during the early and middle 1900s, it is now identified as one of the most significant risk factors for cardiovascular (CV) disease. Increasing awareness and diagnosis of hypertension, and improving control of BP with appropriate treatment, are considered critical public health initiatives to reduce CV morbidity and mortality. Hypertension is an important public health challenge in both economically developing and developed countries. In India, cardiovascular diseases (CVDs) are estimated to be responsible for 1.5 million deaths annually. Hypertension is a major risk factor for CVDs, including stroke and myocardial infarction, and its burden is increasing disproportionately in developing countries as they undergo demographic transition.

Complications of Hypertension

• Stroke

• Cerebral/brainstem infarction

• Cerebral haemorrhage

• Lacunar syndromes

• Multi-infarct disease

• Hypertensive encephalopathy/ malignant hypertension

• Dissecting aortic aneurysm

• Hypertensive nephron-sclerosis

• Peripheral vascular disease (Walker R et al., 2012)

Globally CKD is a major threat because of an increasing incidence, long term hospital stay, high cost of treatment and poor outcome associated with various complications and co-morbidities. CKD is an array of heterogeneous disorders affecting renal architecture and function as well. The Kidney Disease Outcomes Quality Initiative (KDOQI) of the National Kidney Foundation defines CKD as kidney damage and/or a decreased glomerular filtration rate of less than 60 mL/min/1.73 m2 for three months or more. Hypertension (HTN) has been reported in most of patients with CKD (Stages III-V). (Kearney PM et al., 2004)

In India, the incidence of CKD is rising, and as per estimates from 006, the age-adjusted incidence rate of end-stage renal disease (ESRD) is 229 per million populations. Further, the number of new patients entering renal replacement programs annually is >100,000. The rising incidence of CKD in India is likely to burden healthcare and the economy in the future (Walker R et al., 2012).

Study Criteria

Inclusion Criteria:

• Patients treated for hypertension and chronic kidney disease with or without other co morbid conditions like Diabetes mellitus, and other associated cardiovascular diseases.

Exclusion Criteria:

• Pregnant and lactating patients.

• Age below 18 and above 90 years.

• Terminally ill patients co-infected with HIV or Hepatitis or with any infective conditions or with any autoimmune diseases or continuing medications for the same.

• Patients with renal transplant.

Material and Methods

A descriptive, prospective and hospital-based study was conducted in Jayanagar General Hospital, Bangalore over a period of 6 months, after obtaining the clearance and approval from the Institutional Ethics Committee, 70 in-patients were included in the study. The patients were diagnosed of having Chronic Kidney Disease by the consultant Nephrologist according to KDOQI guidelines.

Statistical analysis

Descriptive statistics is done by measuring different proportions. statistical measurement was done in SPSS trial version 24.0. Graphical representation was done in using Microsoft Excel.


Gender wise distribution

During the study period, a total of 70 hypertensive patients were included. Out of 70 patients, 38 (54.2%) were male and 32 (45.8%) were females (Table 1 and Figure 1).

Table 1: Gender wise distribution of patients

S. No Gender Numbers Percentage (%)
1 Male 38 54.2
2 Female 32 45.8

Figure 1. Gender wise distribution of patients.

Age wise distribution

Out of 50 patients, 37 (52.8%) belonged to age group of 41-60 years, followed by 17 (24.2%) belonged to 61-80 years and 12 (17.1%) belonged to 21-40 years. Mean age in study subject was 52.08 ± 15.14 years (Table 2).

Table 2: Age wise distribution of hypertension

S. No Age group Total No Males Females Total percentage (%)
1 18-20 2 1 1 2.8
2 21-40 12 6 6 17.1
3 41-60 37 23 14 52.8
4 61-80 17 7 10 24.2
5 >80 2 1 1 2.8

Distribution of patients based on social habits

Out of 70 patients, we found that 13 (18.5%) patients were smokers alone in which 8 (61.5%) were males and 5 (38.4%) were females and 14 (20%) patients were alcoholic in which 8 (57.1%) were males and 6 (42.8%) were in females. Patients having habit of both alcoholic and smoking were found to be 23 (32.8%) in which 19 (82.6%) were males and 4 917.3%) were females. 20 patients have not had any habits mentioned (Table 3).

Table 3: Social habits of the patients

S. No. Social Habits Total Male Female
1 Smokers 13 8 5
2 Alcoholics 14 8 6
3 Both 23 19 4
4 None 20 3 17

Comorbid conditions

Majority of the patients were suffering from concurrent diabetes mellitus (50%). Other commonly associated conditions were Anaemia (15.7%), Cardiovascular Disease (0.42%), Urinary Tract Infection (0.57%), Chronic Liver Disease (0.14%), Pulmonary Tuberculosis (0.14%), Hypothyroidism (0.28%), Retinopathy (0.14%) and Seizures (0.14%) (Table 4 and Figure 2).

Table 4: Co-morbid conditions.

S. No Co-morbid conditions Total Male Female
1 Diabetes Mellitus 35 16 19
2 Anemia 11 6 5
3 Cardiovascular Disease 3 1 2
4 Urinary Tract Infection 3 1 2
5 Chronic Liver Disease 1 1 0
6 Pulmonary Tuberculosis 1 1 0
7 Hypothyroidism 2 0 2
8 Retinopathy 1 1 0
9 Seizures 1 1 0

Figure 2. Co-morbid conditions.

Antihypertensive drugs use pattern

In our study, out of 70 patients we concluded that 39 patients had received two anti- hypertensive drugs (55.7%), followed by both one and three anti-hypertensive drugs (25.7%) and four antihypertensive drugs. Among the antihypertensive drugs, amlodipine (CCB) was the most commonly prescribed drug (80%) followed by furosemide (loop diuretic) (48.5%), metoprolol (beta blocker) (31.4%), cilnidipine (CCB) (11.4%), torsemide (diuretic) (5.7%) telmisrtan (ARB) (5.7%), losartan (ARB) (2.85%), prazosin (alpha blocker) (10%), clonidine (centrally acting alpha-agonist) (10%), metoprolol (beta blocker) (4%) and enalapril (ACEI) (1.42%), chlorothalidone (thiazide diuretic) (1.42%),captopril (ACEI) (1.42%) (Table 5 and Figure 3).

Table 5: Number of prescriptions with anti-hypertensive drugs.

S. No Anti-Hypertensive Drugs either given alone or in
Percentage of
1 Patients treated with Calcium channel blocking agents 91.4
2 Patients treated with Beta - Adreno receptor Blocking agents 31.4
3 Patients treated with Diuretics 54.2
4 Patients treated with ACE inhibitors 2.85
5 Patients treated with Alpha – adreno receptor Blocking agents 10
6 Patients treated with Angiotensin Receptor Antagonist 8.5
7 Patients treated with Centrally acting anti-hypertensive agent

Figure 3. Anti-hypertensive agents use pattern.

Combination therapy (Table 6)

Table 6: Number of combination therapy.

Therapy No. of Prescription Percentage (%)
Mono therapy 18 25.7
Dual Therapy 29 41.4
Triple Therapy 18 25.7
Combination of four 5 7.14

Percentage adherence to ESH 2018 GUIDILINES: HT+CKD

Out of 70 patients 47 were prescribed in accordance to the ESH guidelines European society of hypertension. Percentage adherence to ESH guideline in relation to treatment of hypertensive patients with compelling indication (s) was found to be 67.1% (Table 7).

Table 7: Percentage adherence to European society of hypertension.

Variables No. of prescriptions Percentage (%)
Adherence 47 67.1
Nonadherence 23 32.9

Categorization of hypertensive patients based on blood pressure reading

In our study that included 70 hypertensive CKD patients, 5 were having severe hypertension requiring intensive anti-hypertensive therapy with more than one antihypertensive agent, 13 were having moderate hypertension requiring pharmacological intervention and remaining 32 were in controlled blood pressure. The categorization is done based on ESH Guidelines 2018 (Table 8 and Figure 4).

Table 8: Categorization of hypertensive patients based on blood pressure reading.

S. No. Blood Pressure Reading No. of Patients
1 Hypertension (Grade 1) 16
2 Hypertension (Grade 2) 7
3 Hypertension (Grade 3) 13
4 Hypertension (Normal) 13
5 Hypertension (High Normal) 21

Figure 4. Categorization of hypertensive patients based on blood pressure reading (ESH Guidelines 2018).

Categorization chronic kidney disease patients according to eGFR with MDRD Method

Out of the 70 patients, 42 patients were in stage 5 (60%) among them 26 (61.9%) were male and 16 (38.09%) were female. 13 were in stage 4 (18.5%) among them 6 (46.1%) were male and 7 (53.85) were female. 13 patients were in stage 3 (18.5%) among that 4 (30.7%) were male and 9 (69.2%) were male. 1 patient in stage 1 and 1 patient in stage 2 which of them were male (Table 9 and Figure 5).

Table 9: Categorization chronic kidney disease patients according to eGFR with MDRD method.

S. No. Stages Total patients Male Female
1 Stage 1 1 1 0
2 Stage 2 1 1 0
3 Stage 3 13 4 9
4 Stage 4 13 6 7
5 Stage 5 42 26 16

Figure 5. Categorization chronic kidney disease patients according to eGFR with MDRD method.


Drug utilization study is described as “The marketing, distribution, prescription and utilization of drugs in the society, with special attention to the resulting medical, social and economic consequences” and has the main objective of facilitating the rational use of drugs which is very important in decision making for healthcare set ups. A prescription survey is one of the most effective methods to evaluate the prescribing attitude of doctors. It is also important to consider the guidelines of international regulatory associations on the management of hypertension that will improve prescribing practice of the physicians and ultimately, the clinical standards. This practice will eventually, help to promote rational use of drugs (Abhisek PA et al., 2017).

The study on antihypertensive drug utilization pattern in presence of chronic kidney disease included 70 patients. According to gender wise distribution it was found that males were slightly more predisposed to the HTN with CKD than females. A similar study concluded that male population was (58.4%) slightly at the higher end for the condition than the females, which was like our study (Sarafidis PA et al., 2012; Verberne WR et al., 2019).

Another study in Odisha reveals the mean age of the hypertensive CKD patients was 49.26 ±11.46 years somewhat close to our study results that is 52.08 ± 15.14 years (Abhisek PA et al., 2017).

In our prescription-based survey, the prominent findings were, out of 70 prescriptions, most of the subjects were of the age group between 41-60 years of age. Two patients were found between 18-20 and two above 80 years of age, this distribution shows that the age group of 41-60 were more prone to have CKD along with hypertension. According to a study conducted in Cuttack, majority of the patients were in the age group of 41-60 years compared to other age groups reflecting the similar pattern with our study years (Abhisek PA et al., 2017).

In our survey, combination therapy was most widely prescribed regimen by the physicians. Earlier studies have revealed that an ideal combination must have antihypertensive drugs possessing complementary modes of action that provide a synergistic effect with minimal adverse effects. Most hypertensive diabetic patients with normal renal function require a combination of two to three antihypertensive agents to lower blood pressure to <130/80 mmHg; patients with concomitant chronic kidney disease may require three or more agents. Combination therapy is required for optimal blood pressure control and prevention of cardiovascular, renal and neurological complications.

Out of 70 patients, we found that 13 (18.5%) patients were smokers alone in which 8 (61.5%) were males and 5 (38.4%) were females and 14 (20%) patients were alcoholic in which 8 (57.1%) were males and 6 (42.8%) were in females. Patients having habit of both alcoholic and smoking were found to be 23 (32.8%) in which 19 (82.6%) were males and 4917.3%) were females. 20 patients have not had any habits mentioned.

In this survey, most commonly prescribed monotherapy was calcium channel blocker (80%) in our study corroborate with the study (Bailie GR et al., 2005). In our study the second most used mono therapy was by loop diuretics (48.5%) however in another study, the most prescribed drug class was ACE inhibitors /ARB which is not similar with our results. In elderly patients, the preferred antihypertensive by the physicians were calcium channel blockers (Magvanjav O et al., 2019).

Our study elicited that most of the patient who were hospitalized were in Stage V (60%) followed by stage 4 (18%) and stage 3 (18%).

Co-morbidities associated with hypertension and CKD were seen in all 52 patients, Diabetes mellitus in 67.3%, anaemia in 21% and other conditions included urinary tract infection and those related to CVS. Most of the studies have shown diabetes mellitus as the favourite co-morbidity in the similar patients.

These findings indicate that medication use was consistent with the international recommendations from JNC 8 and European Society of Hypertension among hypertensive CKD patients (James PA et al., 2014).


Amlodipine and furosemide were the most frequently prescribed antihypertensive drugs. Prescription of antihypertensive drugs for some patients with compelling indications (specifically CKD), were very much congruent with ESH guideline. This study highlights some therapeutic rationality in this health centre. However, targeted education of the prescription-givers and dissemination of treatment guideline could facilitate more rational use of drugs and better therapeutic outcomes.

Control of hypertension and maintenance of ideal blood pressure is the root point that would benefit the CKD patients most maintaining their renal health and related complications. Pharmacists must become more vigilant about current guidelines for the treatment as well as the ADR detection of some antihypertensive which can impact renal functions on patients with concomitant hypertension and Chronic Kidney Disease.

Strategies such as patient education and medication assessment can help to optimize care for these patients and slow the progression to chronic kidney disease. Many patients with CKD and hypertension are still out of reach of specialized care. Specific risk factors determined may aid in identifying patients at high-risk for inadequate treatment. Patient and education provider, public health approaches, and health system changes are needed to address these issues. As the population grows older renal function also tend to decrease proportionally, hence kidney injuries becomes more prominent at the same time condition as hypertension tend to double the risk factor for such age group.


In spite of several limitations like inadequate sample size, study duration, point prevalence nature of the collected data and being unicentric, this study provided a profile of drug utilisation pattern in hypertensive CKD patients compared by class and also individualistic comparison of drugs in the same class. This study will serve as a basis for future comparison. Certain areas like potential drug-drug interaction, AEs and adherence are needed to be explored further.

Fair portion of the drugs were prescribed from the prescribers and all the available medication in hospital were written in generic name. So, it is the need of the hour to avail all the required medication in the institution to prescribe rationally. Continuous prescription audit from the clinical pharmacists in government sector will improve the utilization pattern and therapeutic outcomes in economically challenged hypertensive CKD patients.


  1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC (2017) “Heart disease and stroke statistics- 2017 update: A report from the American Heart Association.” Circ 135: e146-603.
  2. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (2008) “Pharmacotherapy: A pathophysiologic approach” 7th edn, New York, USA. McGraw Hill Medical 139-151.
  3. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J (2004) “Worldwide prevalence of hypertension: a systematic review.” J Hypertens 22: 11-19.
  4. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P (2006) “Disease control priorities in developing countries.” World Bank p: 645-662.
  5. Walker R, Whittlesea C (2012) “Clinical pharmacy and therapeutics.” 5th Ed. Edinburg: Churchill Livingstone. Elsevier p 295-311.
  6. Solanki KC, Mistry RA, Singh AP, Jadav SP, Patel NM, Trivedi HR (2013) “Drug utilization study of anti-hypertensive drugs and their adverse effects in patients of a tertiary care hospital.” J Clin Exp Res 1: 58-67.
  7. Lenfant C, Chobanian AV, Jones DW, Roccella EJ (2003) “Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) resetting the hypertension sails.” Circ 107: 2993-2994.
  8. Ravera M, Re M, Deferrari L, Vettoretti S, Deferrari G (2006) “Importance of blood pressure control in chronic kidney disease.” J Am Soc Nephrol 17: S98-103.
  9. Morgado E, Neves PL (2012) “Hypertension and chronic kidney disease: cause and consequence–therapeutic considerations. In Antihypertensive drugs” IntechOpen p: 45-66.
  10. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S (2003) “Blood pressure predicts risk of developing end-stage renal disease in men and women.” Hypertens 41: 1341-1345.
  11. Verberne WR, Das-Gupta Z, Allegretti AS, Bart HA, Van Biesen W, García-García G, Gibbons E, Parra E, Hemmelder MH, Jager KJ and Ketteler M (2019) “Development of an International Standard Set of Value-Based Outcome Measures for Patients With Chronic Kidney Disease: A Report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group.” Am J Kidney Dis 73: 372-384.
  12. Abhisek PA, Panda R, Samal R, Mohapapatra N, Mohanty S (2017) “Drug utilisation pattern and adverse events in patients with chronic kidney disease undergoing maintenance haemodialysis at a Tertiary Care Hospital of Odisha.” J Clin Diagn Res 11: 11-16.
  13. Abraham G, Arun K, Gopalakrishnan N, Renuka S, Pahari DK, Deshpande P, Isaacs R, Chafekar DS, Kher V, Almeida AF, Sakhuja V (2017) “Management of hypertension in chronic kidney disease: Consensus statement by an expert panel of Indian nephrologists.” J Assoc Physicians India 65: 6-22.
  14. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC (2014) “evidence-based guideline for the management of high blood pressure in adults: A report from the panel members appointed to the Eighth Joint National Committee (JNC 8).” JAMA 311: 507-520.
  15. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J (2000) “Preserving renal function in adults with hypertension and diabetes: a consensus approach.” Am J Kidney Dis 36: 646-661.
  16. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, De Simone G, Dominiczak A, Kahan T (2018) “2018 ESC/ESH Guidelines for the management of arterial hypertension.” Eur Heart J 39: 3021-3104.
  17. Rahman M, Griffin V (2004) “Patterns of antihypertensive medication use in hemodialysis patients.” Am J Health Syst Pharm 61: 1473-1478.
  18. Berbari AE, Daouk NA, Daouk MM (2015) “Chronic Kidney Disease and Renovascular Interactions.” InArterial Dis p: 299-312.
  19. Kalra S,Sahay M, Baruah MP, Agrawal N, Kapoor D, Mitra S (2009) “Management Of Hypertension In Renal Disease: Results From The Imperial Study.” Int J Fam Pract 8
  20. Kalaitzidis RG, Karasavvidou D and Siamopoulos KC (2011) “Hypertension and Chronic Kidney Disease: Pathophysiology and Management Strategies.” BANTAO J 9: 49-58.
  21. Gupta A, Gupta P (2017) “Hypertension in CKD - Management Issues.” Assoc Physicians India C: 142.
  22. Judd E, Calhoun DA (2015) “Management of hypertension in CKD: beyond the guidelines.” Adv Chronic Kidney Dis 22: 116-122.
  23. Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L (2002) “Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.” JAMA 288: 2421-2431.
  24. Levin NW, Kotanko P, Eckardt KU, Kasiske BL, Chazot C, Cheung AK, Redon J, Wheeler DC, Zoccali C, London GM (2010) “Blood pressure in chronic kidney disease stage 5D—A report from a kidney disease: Improving Global Outcomes Controversies Conference.” Kidney Int 77: 273-284.
  25. Bailie GR, Eisele G, Liu L, Roys E, Kiser M, Finkelstein F, Wolfe R, Port F, Burrows-Hudson S, Saran R (2005) “Patterns of medication use in the RRI-CKD study: Focus on medications with cardiovascular effects.” Nephrol Dial Transplant 20: 1110-1115.
  26. Sarafidis PA, Sharpe CC, Wood E, Blacklock R, Rumjon A, Al-Yassin A, Ariyanayagam R, Simmonds S, Fletcher-Rogers J, Vinen K (2012) “Prevalence, patterns of treatment, and control of hypertension in predialysis patients with chronic kidney disease.” Nephron Clin Pract 120: 147-155.
  27. Okuda T, Okamura K, Shirai K, Urata H (2018) “Effect of angiotensin-converting enzyme inhibitor/calcium antagonist combination therapy on renal function in hypertensive patients with chronic kidney disease: Chikushi Anti-Hypertension Trial- Benidipine and Perindopril.” J Clin Med Res 10: 117.
  28. Marín R, Fernández-Vega F, Gorostidi M, Ruilope LM, Díez J, Praga M, Herrero P, Alcázar JM, Laviades C, Aranda P (2006) “Blood pressure control in patients with chronic renal insufficiency in Spain: A cross-sectional study.” J Hypertens 24: 395- 402.
  29. Magvanjav O, Cooper‐DeHoff RM, McDonough CW, Gong Y, Segal MS, Hogan WR, Johnson JA (2019) “Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease.” J Clin Hypertens 21: 91-101.
  30. Ku E, McCulloch CE, Vittinghoff E, Lin F, Johansen KL (2018) “Use of antihypertensive agents and association with risk of adverse outcomes in chronic kidney disease: Focus on angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers.” J Am Heart Assoc 7: e009992.
  31. Teo BW, Chua HR, Wong WK, Haroon S, Subramanian S, Loh PT, Sethi S, Lau T (2016) “Blood pressure and antihypertensive medication profile in a multiethnic Asian population of stable chronic kidney disease patients.” Singapore Med J 57: 267.
  32. Tozawa M, Iseki K, Iseki C, Oshiro S, Higashiuesato Y, Yamazato M, Tomiyama N, Tana T, Takishita S (2002) “Analysis of drug prescription in chronic haemodialysis patients.” Nephrol Dial Transplant 17: 1819-1824.
  33. Lopes AA, Bragg-Gresham JL, Ramirez SP, Andreucci VE, Akiba T, Saito A, Jacobson SH, Robinson BM, Port FK, Mason NA, Young EW (2009) “Prescription of anti-hypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS.” Nephrol Dial Transplant 24: 2809-2816.
  34. Manley HJ, McClaran ML, Overbay DK, Wright MA, Reid GM, Bender WL, Neufeld TK, Hebbar S, Muther RS (2003) “Factors associated with medication- related problems in ambulatory hemodialysis patients.” Am J Kidney Dis 41: 386- 393.